Dr. Abbas Ghayoor Chotana (LUMS), Dr. Shaper Mirza (LUMS) and Dr. M. Tariq (SIHS)
Urinary tract infections (UTIs) are amongst the common infections caused chiefly by uropathogenic Escherichia coli (UPEC), which account nearly 80% of such infections. UTIs are becoming increasingly difficulty to treat owing to the rapid spread of drug resistance among Gram-negative bacilli, unambiguously UPEC (1).
Staphylococcus aureus is a ubiquitous bacterium and around 30% of the human population is colonized with S. aureus (2). It is a major human pathogen that causes a wide-ranging clinical infections, including bacteremia, infective endocarditis, skin and soft tissue infections, respiratory tract infections, and device-related infections.
Infection due to S. aureus inflicts an increasing liability on healthcare capitals. An increasing distress is the emergence of methicillin-resistant S. aureus (MRSA) infections in patients with no obvious risk factor (3). The increasing frequencies of infections caused by such pathogens,particularly in developing countries, has headed towards misuse of broad spectrum antibiotics aiding the development of multi drug resistant (MDR)bacteria and limiting the options for anti biotic therapy. Thus there is a need to develop new antimicrobials to combat infections caused by these pathogens.